Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332627 | 1.00 | TBXA2R (0.33) | TBXA2RTMEM97SIGMAR1CA2TBXAS1 | |
| SCHEMBL3332959 | 1.00 | TBXA2R (0.33) | TBXA2RTMEM97SIGMAR1CA2TBXAS1 | |
| SCHEMBL3465825 | 0.83 | UGT2B7 (0.34) | TBXA2RTMEM97SIGMAR1CA2TBXAS1 | |
| SCHEMBL7364468 | 0.81 | CA2 (0.34) | TBXA2RTMEM97SIGMAR1CA2TBXAS1 | |
| SCHEMBL31274491 | 0.81 | TSHR (0.41) | TBXA2RTMEM97SIGMAR1HCRTR2HCRTR1 | |
| SCHEMBL13299700 | 0.80 | CTDSP1 (0.36) | CA2ALDH1A1SMN1; SMN2 | |
| SCHEMBL14107378 | 0.78 | CA2 (0.32) | CA2 | |
| SCHEMBL12540514 | 0.78 | CA2 (0.32) | CA2 | |
| SCHEMBL12540047 | 0.78 | CA2 (0.32) | CA2 | |
| SCHEMBL5338406 | 0.77 | HCRTR2 (0.33) | TMEM97SIGMAR1CA2HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889660-B2 | Methods for treating obesity or an obesity related condition | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130072555-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-03-21 | — | — | US | disclosed |
| US-8338394-B2 | Methods for treating metabolic diseases | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100135977-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-03 | — | — | US | disclosed |
| WO-2008063768-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072555-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | GPR119, CYP27A1, HSD17B13 | TBXA2R 383/4885TMEM97 1971/4885SIGMAR1 3077/4885 |
| US-20100135977-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | CYP27A1, HSD17B13, GPR119 | TBXA2R 577/4885TMEM97 4358/4885SIGMAR1 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.